Research focus/cooperations

Research focus: Translational prostate cancer research

since 2018 Deep learning for prostate cancer MRI diagnosis (Dr. Gabrani, IBM Zürich Research Laboratory, PD Dr. Patak, Klinik Hirslanden Zürich)
since 2016 Co-Coordinator, Phase IIIb randomized trial comparing irradiation plus long-term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG (Pegasus), EORTC protocol 1414 ROG-GUCG
since 2014 MRI-characteristics of locally advanced Prostate Cancer (Prof. Hadaschik, PD Dr. Wetter, Universität Essen)
since 2013 Co-PI, Perioperative anti-PD-L1 antibody durvalumab (MEDI4736) in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer, SAKK 06/17
since 2011 Movember Global Action Plan 6 (GAP6) Oligometastatic Prostate cancer, Steering committee member (Movember foundation, Australia, USA)
since 2007 Identification of genomic determinants of tumor and metastasis heterogeneity of high risk prostate cancer and development of a lethal prostate cancer panel. (Prof. Rubin, PD Dr. Kruithof de Julio, Bern)
since 2007 Tissue Metabolomic profiles and their alterations in surgically treated high risk prostate cancer. Institute of Pathology, Helmholtz Zentrum München, German Research Center for Environmental Health (Prof. A. Walch)
since 2007 Serum Metabolomic profiles and their alterations in prostate cancer, University Institute for Clinical Chemistry, University of Bern (Profs. M. Fiedler, C. Largadier)
since 2007 EORTC (European Organisation for Research and Treatment of Cancer)
since 2007 Coordinator of the interdisciplinary translational research platform SPECTApros (“Screening Program for Efficient Clinical Trial Access”) (EORTC-1404)
since 2007 Member of the SPECTA steering committee (since 7/2014)
since 2007 Member of the Quality Assurance Committee (since 1/2016)
since 2007 Board Member of the EORTC-Genito Urinary Cancer Group (since 2/2016)
since 2007 Member of the “International Renal Cell Carcinoma-Venous Thrombus Consortium” (IRCC-VTC)
since 2007 Identification and functional characterization of serum circulating microRNAs for prostate cancer risk assessment (DKFZ Hei-delberg, Working Group Clinical Genome Research, Prof. Sültmann).
since 2007 Development of new prognostic biomarkers in prostate cancer, Laboratory of Biosignaling & Therapeutics, Department of Cellular and Molecular Medicine, KU Leuven, Belgium (Prof. Bollen)
since 2007 Molecular Characterization of Tumor Suppressor and Oncomicro-RNAs in vitro and in vivo (Molecular Urooncology University of Würzburg, Dr. Kneitz; Urooncological Research Laboratory University of Bern, Mrs. Dr. M. Kruithof-de Julio, Dr. M. Cecchini)
since 2007 ICo-founder and Steering Committee Member of the “European Clinical and Translational High Risk Prostate Cancer Research Group”
since 2007 Operative treatment of the high-risk prostate cancer
since 2007 Identification and molecular characterization of lethal prostate cancer
since 2007 Biomarker identification and validation